CUREVAC NV (CVAC) Stock Price & Overview
NASDAQ:CVAC • NL0015436031
Current stock price
The current stock price of CVAC is 4.66 USD. Today CVAC is down by -0.21%. In the past month the price decreased by -8.98%. In the past year, price increased by 10.69%.
CVAC Key Statistics
- Market Cap
- 1.049B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.82
- Dividend Yield
- N/A
CVAC Stock Performance
CVAC Stock Chart
CVAC Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CVAC. When comparing the yearly performance of all stocks, CVAC is a bad performer in the overall market: 68.51% of all stocks are doing better.
CVAC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CVAC. CVAC has only an average score on both its financial health and profitability.
CVAC Earnings
On November 24, 2025 CVAC reported an EPS of -0.08 and a revenue of 54.13M. The company beat EPS expectations (30.28% surprise) and beat revenue expectations (396.01% surprise).
CVAC Forecast & Estimates
11 analysts have analysed CVAC and the average price target is 5.57 USD. This implies a price increase of 19.51% is expected in the next year compared to the current price of 4.66.
For the next year, analysts expect an EPS growth of -163.99% and a revenue growth -84.14% for CVAC
CVAC Groups
Sector & Classification
CVAC Financial Highlights
Over the last trailing twelve months CVAC reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS decreased by -247.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 182.11% | ||
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| Debt/Equity | 0.03 |
CVAC Ownership
CVAC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.9 | 364.65B | ||
| AMGN | AMGEN INC | 15.33 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.96 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.63 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.77 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.7 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.41 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.64 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 341.89 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CVAC
Company Profile
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Company Info
IPO: 2020-08-14
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG 72076 DE
CEO: Franz-Werner Haas
Employees: 825
Phone: 49707198830
CUREVAC NV / CVAC FAQ
Can you describe the business of CUREVAC NV?
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Can you provide the latest stock price for CUREVAC NV?
The current stock price of CVAC is 4.66 USD. The price decreased by -0.21% in the last trading session.
Does CUREVAC NV pay dividends?
CVAC does not pay a dividend.
What is the ChartMill technical and fundamental rating of CVAC stock?
CVAC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for CVAC stock?
11 analysts have analysed CVAC and the average price target is 5.57 USD. This implies a price increase of 19.51% is expected in the next year compared to the current price of 4.66.
What is the expected growth for CVAC stock?
The Revenue of CUREVAC NV (CVAC) is expected to decline by -84.14% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.